Among respondents who lost over 20% of body weight, 52% had behavioral and psychological support. Nearly a third switched platforms, most often over price.
Recap by typeshit. Full story at Yahoo.
Avi Roy points out that the largest test so far found no memory benefit from the drug in Ozempic, despite hopes raised by health record studies.
Balwinder Singh and Raman Baweja link GLP-1 use to less kidney replacement therapy in bipolar patients with CKD, and flag lithium toxicity cases.
Yale Medicine says 5% to 10% of people on GLP-1 weight loss drugs see little result, and points to diet as one factor that can blunt the effect.
24:26
A doctor's explainer sorting peptides into eight broad categories. An evergreen overview for anyone still learning the basics.
42:08
Dr. Ana Maria Kausel talks about changing body composition on Mounjaro, Ozempic, Wegovy and Zepbound, with a focus on more than the number on the scale.
A nationwide recall now covers a GLP-1 injectable. The full story names the affected medication and explains why it was pulled.
Loading…